Literature DB >> 14511257

Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis.

D K Petkova1, C A Clelland, J E Ronan, S Lewis, A J Knox.   

Abstract

AIMS: To test the hypothesis that cyclooxygenase (COX)-1 or COX-2 expression is defective in lungs in idiopathic pulmonary fibrosis (IPF) and to characterize the cellular distribution. IPF is a progressive inflammatory lung disorder with an adverse prognosis. Previous work has shown that prostaglandin E2 (PGE2) regulates collagen deposition and fibroblast proliferation and a defect in COX regulation may contribute to the fibrosis that occurs in IPF.
METHODS: Immunohistochemistry was utilized to determine COX immunoreactivity in lung sections from 25 IPF, six sarcoidosis and 14 control subjects.
RESULTS: COX-1 and COX-2 expression in bronchiolar epithelial cells was significantly lower in IPF and sarcoidosis than in controls. No significant difference was found in COX-2 expression between macrophages in IPF and control sections, but COX-2 was reduced in macrophages in sarcoidosis compared with controls.
CONCLUSIONS: These studies confirm COX-2 loss in bronchial epithelial cells but not macrophages in IPF, and show for the first time reduced constitutive COX-1 expression in epithelial cells and macrophages. Similar abnormalities were observed in sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511257     DOI: 10.1046/j.1365-2559.2003.01718.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  26 in total

1.  Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal:  J Clin Immunol       Date:  2011-10-07       Impact factor: 8.317

Review 2.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 3.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

4.  Diallyl disulfide inhibits proliferation and transdifferentiation of lung fibroblasts through induction of cyclooxygenase and synthesis of prostaglandin E₂.

Authors:  Yanhua Wang; Rong Cao; Bo Wei; Xiaoyu Chai; Dan Sun; Y Guan; Xin-min Liu
Journal:  Mol Cell Biochem       Date:  2014-04-23       Impact factor: 3.396

5.  Special Delivery: A New Package for an Old Antifibrotic Mediator.

Authors:  Loka R Penke; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2019-03       Impact factor: 6.914

Review 6.  Epithelial-mesenchymal interactions in pulmonary fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

7.  Regulation of Stem Cell Function in an Engineered Vocal Fold-Mimetic Environment.

Authors:  Aidan B Zerdoum; Pooya Saberi; Alexander J Stuffer; Dakota J Kelly; Randall L Duncan; Luc Mongeau; Xinqiao Jia
Journal:  Regen Eng Transl Med       Date:  2020-01-21

8.  Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis.

Authors:  Christopher D Wiley; Alexis N Brumwell; Sonnet S Davis; Julia R Jackson; Alexis Valdovinos; Cheresa Calhoun; Fatouma Alimirah; Carlos A Castellanos; Richard Ruan; Ying Wei; Harold A Chapman; Arvind Ramanathan; Judith Campisi; Claude Jourdan Le Saux
Journal:  JCI Insight       Date:  2019-12-19

9.  Prostaglandin E2 is activated by airway injury and regulates fibroblast cytoskeletal dynamics.

Authors:  Vlad C Sandulache; Tripti Singh; Ha Sheng Li-Korotky; Chia Y Lo; Todd D Otteson; Mark Barsic; Joseph E Dohar; Patricia A Hebda
Journal:  Laryngoscope       Date:  2009-07       Impact factor: 3.325

10.  Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.

Authors:  Justyna Kiszałkiewicz; Wojciech J Piotrowski; Dorota Pastuszak-Lewandoska; Paweł Górski; Adam Antczak; Witold Górski; Daria Domańska-Senderowska; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Ewa Brzeziańska-Lasota
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.